De-risking psychedelics: Compass Pathways, Cybin and Atai
Jan 09, 2024•48 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
Alex Carchidi updates us on the psychedelic sector and what critical catalysts are approaching (1:30). Why Compass Pathways, Cybin, and Atai make the most sense for investors at this point (15:00). Pros and cons of 4 main industry stocks, including MindMed (29:50).
Episode transcripts
Show Notes:
Psychedelic Stocks = Super-Risky Biotechs Low On Cash. Make Small Bets.
Psychedelic Stocks: Don't Bet On Just 1 Company
Psychedelic Sunday: Scrutinizing Psychedelic Stocks
Cybin: A Leading Early-Stage Psychedelics Play
For full access to analyst ratings, stock quant scores and dividend grades: seekingalpha.com/subscriptions
Cannabis Investing Podcast on Twitter
Episode transcripts
Show Notes:
Psychedelic Stocks = Super-Risky Biotechs Low On Cash. Make Small Bets.
Psychedelic Stocks: Don't Bet On Just 1 Company
Psychedelic Sunday: Scrutinizing Psychedelic Stocks
Cybin: A Leading Early-Stage Psychedelics Play
For full access to analyst ratings, stock quant scores and dividend grades: seekingalpha.com/subscriptions
Cannabis Investing Podcast on Twitter
For the best experience, listen in Metacast app for iOS or Android